What is the equity of Cyclopharm this year?
Cyclopharm has equity of 32.26 M AUD this year.
Cyclopharm Equity 2024
Cyclopharm Equity
32.26 M AUD
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2024, Cyclopharm's equity was 32.26 M AUD, a -11.71% increase from the 36.54 M AUD equity in the previous year.
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Cyclopharm's Equity
Cyclopharm's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cyclopharm's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Cyclopharm's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Cyclopharm's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Cyclopharm’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Cyclopharm stock
What was the equity of Cyclopharm compared to the previous year?
The equity of Cyclopharm has increased/decreased by -11.71% decreased compared to the previous year.
What impact does a high equity have on investors of Cyclopharm?
A high equity is advantageous for investors of Cyclopharm as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Cyclopharm?
A low equity can be a risk for investors of Cyclopharm, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Cyclopharm affect the company?
An increase in equity of Cyclopharm can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Cyclopharm affect the company?
A reduction in equity of Cyclopharm can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Cyclopharm?
Some factors that can affect the equity of Cyclopharm include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Cyclopharm so important for investors?
The equity of Cyclopharm is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Cyclopharm take to change the equity?
To change equity, Cyclopharm can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 0.73 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.01 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 0.73 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 0 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to 0.01 AUD are expected. This corresponds to a dividend yield of 0.68 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2023?
In the year 2023, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
